Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
Alnylam Pharmaceuticals, Inc. announced today that it has granted Bio-Rad a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"Execution of this license agreement with Bio-Rad, a global leader in the life science research community, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Roland Kreutzer, Ph.D., Managing Director of Alnylam Europe AG. "This agreement brings the number of licenses that Alnylam has granted to more than 20, including 13 with research product suppliers. In fact, we believe that over 75 percent of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam's intellectual property."
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Phenomenex President and CEO Fasha Mahjoor Named Finalist for Ernst & Young Entrepreneur of the Year 2010 Awards
Anton Paar establishes subsidiary in Mexico
LAB901 Ltd. partners with South Korean PCR diagnostics firm, Seegene Inc.
Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement - Single-Molecule DNA Sequencing System Promises Dramatic Improvement in Cost, Speed, Versatility, and Simplicity of Sequencing
DESY X-ray lightsource identifies promising candidates for COVID drugs - Existing active substances bind to key virus protein
Merck KGaA to acquire all outstanding Millipore shares for US$ 107 per share in cash - Combination will create a € 2.1 billion (US$ 2.9 billion) partner for the Life Science sector and transform Merck Chemicals
A sub-femtosecond stop watch for 'photon finish' races
Silent carriers of malaria are unlikely to develop the disease